was spatulated and approximated to a distal cystotomy. The detrusor tunnel was closed. The Mitrofanoff was pulled through the umbilical port, spatulated, and anastamosed. Catheters were left in the Mitrofanoff channel and the urethra. EBL was 30mL and total OR time was 640 minutes. The treatment of retrograde ejaculation (RE) is important not only for fertility but also for satisfaction of sexual intercourse. Ideally, the goal of treatment is to establish antegrade ejaculation, not only for the sperm retrieval. The use of sympathomimetics for the treatment of RE is well-known, however the overall success rate does not exceed 50%. The aim of the present study is to evaluate the efficacy of buspirone (nonbenzodiazepine anxiolytics) in neurogenic RE. METHODS: The complete RE patients who were refractory to previous pseudoephedrine treatment included in the study. RE was diagnosed in patients who complained absence of ejaculated after orgasm and identified sperm in a post-ejaculatory urine sample. The patients who were taking alpha-adrenergic blocker and psychotropic medication, and who were taken the bladder neck or transurethral resection of the prostate, were excluded in this study. All patients were given buspirone 5mg twice/day for 4 weeks. We evaluated the efficacy of buspirone by the establishment of antegrade ejaculate after 4 weeks of treatment.
INTRODUCTION AND OBJECTIVES:
The treatment of retrograde ejaculation (RE) is important not only for fertility but also for satisfaction of sexual intercourse. Ideally, the goal of treatment is to establish antegrade ejaculation, not only for the sperm retrieval. The use of sympathomimetics for the treatment of RE is well-known, however the overall success rate does not exceed 50%. The aim of the present study is to evaluate the efficacy of buspirone (nonbenzodiazepine anxiolytics) in neurogenic RE.
METHODS: The complete RE patients who were refractory to previous pseudoephedrine treatment included in the study. RE was diagnosed in patients who complained absence of ejaculated after orgasm and identified sperm in a post-ejaculatory urine sample. The patients who were taking alpha-adrenergic blocker and psychotropic medication, and who were taken the bladder neck or transurethral resection of the prostate, were excluded in this study. All patients were given buspirone 5mg twice/day for 4 weeks. We evaluated the efficacy of buspirone by the establishment of antegrade ejaculate after 4 weeks of treatment.
RESULTS: Total 26 patients were diagnosed with complete RE refractory to pseudoephedrine. 5 of 26 were excluded due to previous history of bladder neck surgery and psychotropic medication. The most common etiologies were diabetes mellitus (42.9%) and idiopathic (28.6%). Other etiologies were identified as follows: spinal cord injury (19.0%), parkinson's disease (4.8%) and multiple sclerosis (4.8%). Twelve of 21 patients (57.1%) were achieved antegrade ejaculation. One patient discontinued the study due to adverse events (developing dizziness) and one patient had mild dyspepsia; the remaining patients had no adverse drug-related events.
CONCLUSIONS: In patients with neurogenic RE, buspirone was effective for inducing antegrade ejaculation in more than 50% of patients. We suggest that if the first line treatments such as pseudoephedrine or imipramine are not effective, buspirone may be warranted.
Source of Funding: none

MP52-02 SAFETY AND EFFECTIVENESS OF PLATELET-RICH PLASMA FOR MALE INFERTILITY IMPROVEMENT IN RATS
Maya Epifanova*, Badri Gvasalia, Maksim Durashov, Sergey Artemenko, Moscow, Russian Federation INTRODUCTION AND OBJECTIVES: The purpose of the trial was to evaluate Platelet-rich plasma (PRP) modifications safety and effectiveness for treating experimentally induced azoospermia in rat model. Busulfan-induced azoospermia (BIA) model and Cisplatininduced azoospermia (CIA) model were tested. CIA model failed because of its profound cytotoxic effect, distant rats death and irreversible thrombocytopenia. BIA model was used.
METHODS: 80 adult male Wistar rats weighing 250-300g were randomly assigned in 5 equal groups. Rats of 4 experimental groups (EG) received 10 mg/kg intraperitoneal Busulfan injections twice to induce azoospermia. 0.9% saline solution was administered in peritoneal cavity of the control group (CG) rats. Each EG received one of the following PRP modification injection (50 µL/testis) -Poor PRP, PRP, PRP activated with 10% of CaCl 2 (a-PRP), Leukocyte-and Platelet-Rich Plasma (L-PRP). PRP was administered 1 time a week during 6 weeks following Busulfan injection. Whole blood for PRP processing was obtained from inbred donors. Rats reproductive organs weight, body weight, complete blood count (CBC), epididymal sperm count, sperm motility and morphology were assessed on 14 th , 28 th , 42 nd day after PRP administration. RESULTS: Total body weight did not change. However, weight gain in EG was suppressed by 42 nd day by comparison with CG. CBC in experimental groups was reduced by the second week after Busulfan injection and reached CG levels by 42 nd day (p<0.05). Reproductive organs mass was reduced in the EG (p<0.05). Epididymal sperm count was increased in a-PRP, L-PRP groups compared to CG at 42 nd day after receiving a-PRP and L-PRP (p<0.05). Spermatozoa with abnormal morphology counts were increased by 42 nd day (p<0.05) and correlated with the decrease of their motility (p<0.05) in EG. Histologically, there were severe seminiferous epithelium disorganization and testicular parenchyma swelling, as well as reduction of diameter of the seminiferous tubules (p<0.05).
CONCLUSIONS: PRP-therapy is a safe method for rats' spermatogenesis recovery. The next aim for the trial is to evaluate PRPtherapy effectiveness for spermatogenesis recovery. Excessive spermatogenesis suppression was found in BIA rats. Reproductive cells damage and inflammation induction was due to frequently performed intratesticular PRP injection. The final assessment should be made on 60 th day because of the amount of time taken to produce spermatozoa in the rat testis.
Source of Funding: None
MP52-03 BARIATRIC SURGERY IMPACT ON ERECTILE FUNCTION, SEMEN PARAMETERS AND SEXUAL HORMONES IN OBESE MEN
Guilherme Wood*, Bruno Tiseo, Joao Paulo Cardoso, Hamilton de Martin, Marco Aurelio Santo, Miguel Srougi, Marcello Antonio Cocuzza, Sao Paulo, Brazil INTRODUCTION AND OBJECTIVES: Despite the major importance of obesity as a global healthy issue, there is a paucity of data regarding its influence on male fertility. Bariatric surgery has become an important treatment option, but little is known of its impact on testicular and sexual function. This study aimed to evaluate the impact of obesity on erectile function, semen analysis (SA) and testicular function, and the influence of bariatric surgery in these parameters.
METHODS: The study was performed on 2 phases. On the first phase 32 healthy fertile controls and 42 obese patients were submitted to complete urological evaluation, IEEF-5 score, SA and dosing of sexual hormones. On phase 2, 22 obese patients (Group A1) were submitted to bariatric surgery and 20 remained on conservative treatment (Group A2). Obese patients were then revaluated 6 months Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e765
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